Clinical trials: G-CSF
Healthy
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
The purpose of the study is to: Establish and evaluate a system for collection of filgrastim-mobilized peripheral blood stem cells from National Marrow Donor Program donors (NMDP) donors Assess the safety among NMDP donors of…
- Trial name
- NCT00785525
- Testing
- Filgrastim
- Where
- 4 sites in United States
- Volunteers
- 60,000 people, healthy volunteers welcome
- Sponsor
- Center for International Blood and Marrow Transplant Research
Healthy
Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors
Peripheral blood stem cells (PBSCs) collected following stimulation with filgrastim are commonly used for autologous hematopoietic transplants.
- Trial name
- NCT00511550
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Chromosome Aberrations
Study on the Impact of Stem Cell Donation and Bone Marrow Harvesting on Unrelated Donors
Granulocyte Colony Stimulating Factor (GCSF) is used extensively as a means of mobilising donor peripheral blood stem cells as an alternative to bone marrow harvesting for the purpose of recipient stem cell transplantation.
- Trial name
- NCT01884610
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University College, London
Idiopathic CD4-Positive, T-Lymphocytopenia
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Idiopathic CD4 lymphocytopenia (ICL) is a rare syndrome defined by consistently low CD4 T cell counts (<300/mm^3) without evidence of HIV infection or other known immunodeficiency.
- Trial name
- NCT02015013
- Testing
- Filgrastim, Plerixafor
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Volunteers
Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects
This study will compare treatment emergent incidence rate of ADA between TPI-120 and US licensed Neulasta in normal healthy adult subjects
- Trial name
- TPI-120 (NCT03202927)
- Testing
- PEGFILGRASTIM
- Where
- 2 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Adello Biologics, LLC
Multiple Myeloma
High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma
This study was a multi-center, randomized, prospective study. The purpose is to clarify that high-dose VP-16+G-CSF has better mobilization efficiency and less toxic and side effects compared with high-dose CTX+G-CSF, and minimize…
- Trial name
- NCT05517213
- Testing
- Etoposide, Cyclophosphamide
- Where
- China
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
This phase II trial is for patients with acute lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndrome or chronic myeloid leukemia who have been referred for a peripheral blood stem cell transplantation to treat…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT02220985
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myelodysplastic Syndrome
GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant
This is a pilot study which will be done in a small number of patients. The purpose of this study is to test the safety and benefit of giving a type of chemotherapy - cyclophosphamide - after the transplant to prevent graft…
- Conditions
- Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
- Trial name
- NCT02360111
- Testing
- Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Stem Cells, Orthopedic Disorder
Stem Cells After Peripheral Mobilization and Harvest
The proposed study is a controlled laboratory study where stem cell content of bone marrow aspirate will be compared prior to and following pharmaceutical mobilization.
- Trial name
- NCT03381599
- Testing
- Filgrastim Injection
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Andrews Research & Education Foundation
Chemotherapy-induced Neutropenia
Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects
This study is designed to access the tolerability and Pharmacokinetic/Pharmacodynamic (PK/PD) of single subcutaneous (SC) injection of GW003 in healthy subjects.
- Trial name
- NCT02643901
- Testing
- GW003
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Healthy
G-CSF for Granulocyte Donation
This study will examine the feasibility of giving cell growth stimulants to granulocyte donors the same day of donation rather than the day before.
- Trial name
- NCT00001842
- Testing
- Granulocyte colony-stimulating factor, Dexamethasone
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Graft-Versus-Host Disease, Graft-versus-leukemia
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Bone marrow transplants (BMT) are one form of treatment for disorders of the blood, including leukemia. However, because the procedure is often associated with potentially life-threatening reactions, it is usually reserved for…
- Conditions
- Graft-Versus-Host Disease, Graft-versus-leukemia, Donor Apheresis
- Trial name
- NCT00001529
- Testing
- G-CSF
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Healthy Volunteers
Effects of CSL324 in the Lung After Segmental Challenge
This is a phase 1b, randomized, double-blind, placebo-controlled study in healthy volunteers to investigate the antiinflammatory effect of pretreatment with CSL324 on response to a lipopolysaccharide (LPS) endotoxin challenge in…
- Trial name
- NCT05653713
- Testing
- CSL324
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Healthy Apheresis Donors, Mononuclear (MNC) Cell Donors
An Evaluation of the Spectra Optia CMNC Collection Procedure
The purpose of this prospective, randomized, cross-over, multi-center study is to evaluate the performance of the Spectra Optia Apheresis System's CMNC Collection Procedure, compared to the COBE Spectra Apheresis System's MNC…
- Trial name
- CMNC (NCT02253160)
- Testing
- Spectra Optia CMNC, COBE Spectra MNC, Granulocyte-colony stimulating factor (G-CSF)
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Terumo BCT
Granulocyte Colony-stimulating Factor, Biliary Atresia
Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.
- Trial name
- NCT06708572
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Liver Institute, Egypt
Healthy
Pharmacokinetics and Pharmacodynamics of a Novel Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor
This study is a four arm, parallel study. Ten were administered a single subcutaneous administration of 30, 100 and 300 μg/kg of GCPGC or placebo for each group (active:placebo=8:2).
- Trial name
- GCPGC (NCT00969826)
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Healthy
Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
Study CSL324_1003 is a single center, randomized, double-blind, placebo-controlled study designed to characterize and compare the PK properties and safety of a single subcutaneous dose of CSL324 in healthy Japanese and White…
- Trial name
- NCT04570267
- Testing
- CSL324
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Healthy Allogeneic Donors, Granulocyte Colony-stimulating Factor (G-CSF) Mobilized
Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®
The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system.
- Trial name
- optiMaL (NCT01901458)
- Testing
- Spectra Optia® IDL-Set, Spectra Optia® Collection Set
- Where
- 2 sites in Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Heinrich-Heine University, Duesseldorf
Neutropenia (Low White Blood Cell Count)
A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
This is a study comparing two study drugs, Filgrastim Hospira and Neupogen®. Neupogen® is approved by the US Food and Drug Administration (FDA) to treat low numbers of specific kinds of white blood cells (WBC) known as…
- Trial name
- NCT02766647
- Testing
- Filgrastim Hospira (US), US-approved Neupogen®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Melanoma, Neoplasm Metastasis
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
This experiment will test the safety and effectiveness of a treatment for melanoma in which certain lymphocytes (a type of white blood cell) are taken from the patient, grown in the laboratory, and returned after the patient's…
- Trial name
- NCT00001832
- Testing
- gp100:209-217 (210M), Montanide ISA-51, IL-2
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)